TBPH 17.07 Theravance Biopharma Inc. $TBPH Hit a 52 week low of 15.67 Currently at 17.07 -0.37 -2.12% With a day low of 15.67 and a total volume of 281,500.
TBPH Theravance Biopharma Inc. Recent Headline News
Theravance Biopharma, Inc. Reports Third Quarter 2014 Financial Results
Marketwired - Thu Nov 06, 3:16PM CST
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"
, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., today reported financial results for the third quarter 2014. Revenue for the third quarter of 2014 was $6.3 million. Net loss for the third quarter of 2014 was $54.5 million or $1.72 per share. Cash, cash equivalents, and marketable securities totaled $350.4 million as of September 30, 2014.
TBPH: 17.07 (-0.37)
Theravance Biopharma Announces Positive Results From Phase 1 Proof-of-Concept Study of TD-6450, an NS5A Inhibitor to Treat Hepatitis C
Marketwired - Mon Nov 03, 3:08PM CST
Theravance Biopharma (NASDAQ: TBPH), through its U.S. operating subsidiary, Theravance Biopharma US, Inc., today announced positive results from the first three cohorts of Study 0110, a Phase 1 proof-of-concept study of TD-6450, a next-generation investigational NS5A inhibitor in development to treat patients with hepatitis C virus infection (HCV).
TBPH: 17.07 (-0.37)
Theravance (THRX) Falls on Wider-than-Expected Loss in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:10AM CST
Theravance reported third-quarter 2014 loss of 19 cents per share.
AMAG: 34.95 (+0.83), TBPH: 17.07 (-0.37), GSK: 44.91 (+0.16), THRX: 14.27 (-0.13)
Theravance Biopharma, Inc. to Report Third Quarter 2014 Financial Results on November 6, 2014
Marketwired - Thu Oct 30, 3:20PM CDT
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company" announced today, through its US operating subsidiary, Theravance Biopharma US, Inc., that it will release financial results for the period ended September 30, 2014, after the market close on Thursday, November 6, 2014.
TBPH: 17.07 (-0.37)
Theravance Reports Third Quarter 2014 Financial Results
Marketwired - Thu Oct 30, 3:06PM CDT
Theravance, Inc. (NASDAQ: THRX) today reported financial results for the quarter ended September 30, 2014 and announced that its Board of Directors approved a $0.25 per share cash dividend to be paid on December 23, 2014 to stockholders of record as of the close of business on November 25, 2014. Royalties received on net sales of RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R) from Glaxo Group Limited (GSK) were $4.0 million. Net loss for the third quarter of 2014 was $21.3 million or $0.19 per diluted share. Cash, cash equivalents, marketable securities and current restricted cash totaled $316.5 million as of September 30, 2014.
THRXV: 28.00 (+7.07), THRX: 14.27 (-0.13), TBPH: 17.07 (-0.37)
Ophthotech Corporation Names Michael G. Atieh as Executive Vice President and Chief Financial and Business Officer
Business Wire - Tue Sep 23, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that Michael G. Atieh has been named Executive Vice President, Chief Financial and Business Officer and Treasurer effective September 30, 2014. Mr. Atieh replaces Bruce A. Peacock, Chief Financial and Business Officer and Treasurer, who has notified the Company of his intention to retire effective September 30, 2014.
ACE: 110.81 (+0.08), MRK: 59.34 (+0.08), OPHT: 41.26 (+0.14), TBPH: 17.07 (-0.37)
Theravance Biopharma Provides VIBATIV(R) (telavancin) Product Update
Marketwire - Tue Sep 09, 7:05AM CDT
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company" today provided a product update for VIBATIV(R) (telavancin), the Company's proprietary FDA-approved bactericidal, once-daily, injectable lipoglycopeptide antibiotic. The Company detailed plans for additional VIBATIV clinical studies, its strategy for increasing the scope of US commercial efforts and new study analyses presented at recent scientific conferences underscoring VIBATIV's in vitro potency and activity. Today's announcement is being made in conjunction with the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) being held September 5-9, 2014 in Washington D.C.
TBPH: 17.07 (-0.37)
Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Dose-Ranging Study of its Investigational LAMA, TD-4208, for the Treatment of COPD
Marketwire - Mon Sep 08, 3:05PM CDT
Theravance Biopharma (NASDAQ: TBPH), through its US operating subsidiary, Theravance Biopharma US, Inc., today announced positive top-line results from its Phase 2b dose-ranging study of TD-4208, an investigational long-acting muscarinic antagonist (LAMA) in development for the treatment of chronic obstructive pulmonary disease (COPD). The study evaluated four doses of TD-4208 (44, 88, 175 and 350 mcg) and placebo, administered once daily for 28 days in a double-blind, parallel group study in a total of 355 patients with moderate-to-severe COPD.
TBPH: 17.07 (-0.37)
Drug M&A Boom Driven By Long-Term Trends: PwC
at Investor's Business Daily - Wed Sep 03, 3:22PM CDT
If you've been feeling like drugmaker mergers and acquisitions have been busting out all over the place this year, professional-services firm PricewaterhouseCoopers has the numbers to back you up. In its second-quarter report on the subject, released...
MNK: 91.06 (-3.49), JNJ: 108.20 (-0.81), CG: 28.94 (+0.68), TBPH: 17.07 (-0.37), THRX: 14.27 (-0.13), BMY: 58.32 (-0.14)
Theravance Biopharma to Present at Investor Conferences in September 2014
Marketwire - Thu Aug 21, 3:05PM CDT
Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Rick E Winningham, Theravance Biopharma's Chief Executive Officer, is scheduled to present at the following investor conferences in September 2014:
TBPH: 17.07 (-0.37)
Theravance Biopharma, Inc. Reports Second Quarter 2014 Financial Results
Marketwire - Wed Aug 13, 3:06PM CDT
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company" today reported financial results for the second quarter 2014, and provided a corporate update. Revenue for the second quarter of 2014 was $3.0 million. Net loss for the second quarter of 2014 was $58.2 million or $1.83 per share. Cash, cash equivalents, and marketable securities totaled $387.4 million as of June 30, 2014.
TBPH: 17.07 (-0.37)
Theravance (THRX) Incurs Narrower-than-Expected Loss in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:10AM CDT
Theravance (THRX) incurred a loss of 18 cents in the quarter.
TBPH: 17.07 (-0.37), GSK: 44.91 (+0.16), THRX: 14.27 (-0.13)
Theravance Reports Second Quarter 2014 Financial Results
Marketwire - Wed Aug 06, 3:08PM CDT
Theravance, Inc. (NASDAQ: THRX) today reported financial results for the quarter ended June 30, 2014 and announced that its Board of Directors approved a $0.25 per share cash dividend to be paid on September 18, 2014 to stockholders of record as of the close of business on August 28, 2014. Royalties earned in the second quarter of 2014 were $3.3 million, which were partially offset by amortization of intangible assets of $2.6 million resulting in net royalty revenues of approximately $0.7 million from Glaxo Group Limited (GSK) related to net sales of RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R) from GSK. Net loss for the second quarter of 2014 was $63.6 million or $0.57 per diluted share. Cash and cash equivalents, short-term investments, marketable securities and current restricted cash totaled $383.1 million as of June 30, 2014.
THRXV: 28.00 (+7.07), THRX: 14.27 (-0.13), TBPH: 17.07 (-0.37)
Theravance, Inc. Appoints Michael W. Aguiar as President and Chief Executive Officer
Marketwire - Wed Aug 06, 3:05PM CDT
Theravance, Inc. (NASDAQ: THRX) ("Theravance" or "Company" today announced that its Board of Directors has appointed Michael W. Aguiar as President and Chief Executive Officer of the Company effective August 15, 2014 and as a member of the Board of Directors effective immediately. Mr. Aguiar plans to continue to serve as Theravance's Senior Vice President and Chief Financial Officer until his replacement is identified and appointed. Mr. Aguiar will replace Rick E Winningham who has resigned as Chief Executive Officer of Theravance effective August 15, 2014. Mr. Winningham will remain Chairman of the Board of Directors of Theravance, Inc. and will transition to full time Chief Executive Officer of Theravance Biopharma, Inc. ("Theravance Biopharma" as of August 15, 2014.
THRXV: 28.00 (+7.07), THRX: 14.27 (-0.13), TBPH: 17.07 (-0.37)
DNAnexus Appoints David Shaywitz as Chief Medical Officer
Business Wire - Tue Aug 05, 6:30AM CDT
DNAnexus, a leader in enterprise solutions for networked genome informatics and data management, today announced the expansion of its senior leadership team with the appointment of David Shaywitz, M.D., Ph.D. as the company's first Chief Medical Officer. Shaywitz joins DNAnexus from Theravance Biopharma and will focus on leveraging the company's pioneering cloud-based genomics platform to drive clinical impact, working closely with management and engineering teams, and with external partners and collaborators.
TBPH: 17.07 (-0.37)
Theravance/Glaxo Commence Global Late stage Study on COPD - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 5:42PM CDT
Glaxo (GSK) and Theravance (THRX) initiated a phase III study in COPD.
TBPH: 17.07 (-0.37), GSK: 44.91 (+0.16), THRX: 14.27 (-0.13)
1 Special Situation Dividend Stock: Snatch Up of Stay Away?
David Williamson, The Motley Fool - Motley Fool - Sun Jul 13, 11:52AM CDT
Biotech Theravance (NASDAQ: THRX) is undergoing a radical transformation. Is this special situation a unique opportunity for dividend investors, or arre problems lurking beneath the surface. Theravance recently split in two, with the money it...
THRX: 14.27 (-0.13), TBPH: 17.07 (-0.37), GSK: 44.91 (+0.16)
Glaxo/Theravance Drug Gets Japanese Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 11:00AM CDT
Glaxo (GSK) and Theravance's (THRX) Anoro Ellipta has been approved in Japan.
TBPH: 17.07 (-0.37), GSK: 44.91 (+0.16), THRX: 14.27 (-0.13), REGN: 377.84 (+0.90)
Board Changes, Patents, Recognitions, and Technical Updates - Analyst Notes on Actavis, Celldex Therapeutics, Galena Biopharma, PTC Therapeutics and Theravance Biopharma
PR Newswire - Fri Jul 04, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Galena Biopharma, Inc. (NASDAQ: GALE), PTC Therapeutics, Inc. (NASDAQ: PTCT) and Theravance Biopharma, Inc. (NASDAQ: TBPH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4461-100free.
ACT: 245.91 (-4.47), CLDX: 13.42 (-0.06), PTCT: 40.24 (-1.93), GALE: 1.95 (-0.09), TBPH: 17.07 (-0.37), FRX: 99.00 (-0.77)
Glaxo/Theravance Seek to Expand Breo Ellipta's Label - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 10:50AM CDT
Glaxo (GSK) and Theravance (THRX) are looking to get Breo Ellipta approved for asthma in the U.S.
TBPH: 17.07 (-0.37), GSK: 44.91 (+0.16), THRX: 14.27 (-0.13), REGN: 377.84 (+0.90)
TBPH Theravance Biopharma Inc. Recent Headline News
Theravance Biopharma, Inc. Reports Third Quarter 2014 Financial Results
Marketwired - Thu Nov 06, 3:16PM CST
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"
, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., today reported financial results for the third quarter 2014. Revenue for the third quarter of 2014 was $6.3 million. Net loss for the third quarter of 2014 was $54.5 million or $1.72 per share. Cash, cash equivalents, and marketable securities totaled $350.4 million as of September 30, 2014. TBPH: 17.07 (-0.37)
Theravance Biopharma Announces Positive Results From Phase 1 Proof-of-Concept Study of TD-6450, an NS5A Inhibitor to Treat Hepatitis C
Marketwired - Mon Nov 03, 3:08PM CST
Theravance Biopharma (NASDAQ: TBPH), through its U.S. operating subsidiary, Theravance Biopharma US, Inc., today announced positive results from the first three cohorts of Study 0110, a Phase 1 proof-of-concept study of TD-6450, a next-generation investigational NS5A inhibitor in development to treat patients with hepatitis C virus infection (HCV).
TBPH: 17.07 (-0.37)
Theravance (THRX) Falls on Wider-than-Expected Loss in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:10AM CST
Theravance reported third-quarter 2014 loss of 19 cents per share.
AMAG: 34.95 (+0.83), TBPH: 17.07 (-0.37), GSK: 44.91 (+0.16), THRX: 14.27 (-0.13)
Theravance Biopharma, Inc. to Report Third Quarter 2014 Financial Results on November 6, 2014
Marketwired - Thu Oct 30, 3:20PM CDT
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"
announced today, through its US operating subsidiary, Theravance Biopharma US, Inc., that it will release financial results for the period ended September 30, 2014, after the market close on Thursday, November 6, 2014. TBPH: 17.07 (-0.37)
Theravance Reports Third Quarter 2014 Financial Results
Marketwired - Thu Oct 30, 3:06PM CDT
Theravance, Inc. (NASDAQ: THRX) today reported financial results for the quarter ended September 30, 2014 and announced that its Board of Directors approved a $0.25 per share cash dividend to be paid on December 23, 2014 to stockholders of record as of the close of business on November 25, 2014. Royalties received on net sales of RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R) from Glaxo Group Limited (GSK) were $4.0 million. Net loss for the third quarter of 2014 was $21.3 million or $0.19 per diluted share. Cash, cash equivalents, marketable securities and current restricted cash totaled $316.5 million as of September 30, 2014.
THRXV: 28.00 (+7.07), THRX: 14.27 (-0.13), TBPH: 17.07 (-0.37)
Ophthotech Corporation Names Michael G. Atieh as Executive Vice President and Chief Financial and Business Officer
Business Wire - Tue Sep 23, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that Michael G. Atieh has been named Executive Vice President, Chief Financial and Business Officer and Treasurer effective September 30, 2014. Mr. Atieh replaces Bruce A. Peacock, Chief Financial and Business Officer and Treasurer, who has notified the Company of his intention to retire effective September 30, 2014.
ACE: 110.81 (+0.08), MRK: 59.34 (+0.08), OPHT: 41.26 (+0.14), TBPH: 17.07 (-0.37)
Theravance Biopharma Provides VIBATIV(R) (telavancin) Product Update
Marketwire - Tue Sep 09, 7:05AM CDT
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"
today provided a product update for VIBATIV(R) (telavancin), the Company's proprietary FDA-approved bactericidal, once-daily, injectable lipoglycopeptide antibiotic. The Company detailed plans for additional VIBATIV clinical studies, its strategy for increasing the scope of US commercial efforts and new study analyses presented at recent scientific conferences underscoring VIBATIV's in vitro potency and activity. Today's announcement is being made in conjunction with the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) being held September 5-9, 2014 in Washington D.C. TBPH: 17.07 (-0.37)
Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Dose-Ranging Study of its Investigational LAMA, TD-4208, for the Treatment of COPD
Marketwire - Mon Sep 08, 3:05PM CDT
Theravance Biopharma (NASDAQ: TBPH), through its US operating subsidiary, Theravance Biopharma US, Inc., today announced positive top-line results from its Phase 2b dose-ranging study of TD-4208, an investigational long-acting muscarinic antagonist (LAMA) in development for the treatment of chronic obstructive pulmonary disease (COPD). The study evaluated four doses of TD-4208 (44, 88, 175 and 350 mcg) and placebo, administered once daily for 28 days in a double-blind, parallel group study in a total of 355 patients with moderate-to-severe COPD.
TBPH: 17.07 (-0.37)
Drug M&A Boom Driven By Long-Term Trends: PwC
at Investor's Business Daily - Wed Sep 03, 3:22PM CDT
If you've been feeling like drugmaker mergers and acquisitions have been busting out all over the place this year, professional-services firm PricewaterhouseCoopers has the numbers to back you up. In its second-quarter report on the subject, released...
MNK: 91.06 (-3.49), JNJ: 108.20 (-0.81), CG: 28.94 (+0.68), TBPH: 17.07 (-0.37), THRX: 14.27 (-0.13), BMY: 58.32 (-0.14)
Theravance Biopharma to Present at Investor Conferences in September 2014
Marketwire - Thu Aug 21, 3:05PM CDT
Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Rick E Winningham, Theravance Biopharma's Chief Executive Officer, is scheduled to present at the following investor conferences in September 2014:
TBPH: 17.07 (-0.37)
Theravance Biopharma, Inc. Reports Second Quarter 2014 Financial Results
Marketwire - Wed Aug 13, 3:06PM CDT
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"
today reported financial results for the second quarter 2014, and provided a corporate update. Revenue for the second quarter of 2014 was $3.0 million. Net loss for the second quarter of 2014 was $58.2 million or $1.83 per share. Cash, cash equivalents, and marketable securities totaled $387.4 million as of June 30, 2014. TBPH: 17.07 (-0.37)
Theravance (THRX) Incurs Narrower-than-Expected Loss in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:10AM CDT
Theravance (THRX) incurred a loss of 18 cents in the quarter.
TBPH: 17.07 (-0.37), GSK: 44.91 (+0.16), THRX: 14.27 (-0.13)
Theravance Reports Second Quarter 2014 Financial Results
Marketwire - Wed Aug 06, 3:08PM CDT
Theravance, Inc. (NASDAQ: THRX) today reported financial results for the quarter ended June 30, 2014 and announced that its Board of Directors approved a $0.25 per share cash dividend to be paid on September 18, 2014 to stockholders of record as of the close of business on August 28, 2014. Royalties earned in the second quarter of 2014 were $3.3 million, which were partially offset by amortization of intangible assets of $2.6 million resulting in net royalty revenues of approximately $0.7 million from Glaxo Group Limited (GSK) related to net sales of RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R) from GSK. Net loss for the second quarter of 2014 was $63.6 million or $0.57 per diluted share. Cash and cash equivalents, short-term investments, marketable securities and current restricted cash totaled $383.1 million as of June 30, 2014.
THRXV: 28.00 (+7.07), THRX: 14.27 (-0.13), TBPH: 17.07 (-0.37)
Theravance, Inc. Appoints Michael W. Aguiar as President and Chief Executive Officer
Marketwire - Wed Aug 06, 3:05PM CDT
Theravance, Inc. (NASDAQ: THRX) ("Theravance" or "Company"
today announced that its Board of Directors has appointed Michael W. Aguiar as President and Chief Executive Officer of the Company effective August 15, 2014 and as a member of the Board of Directors effective immediately. Mr. Aguiar plans to continue to serve as Theravance's Senior Vice President and Chief Financial Officer until his replacement is identified and appointed. Mr. Aguiar will replace Rick E Winningham who has resigned as Chief Executive Officer of Theravance effective August 15, 2014. Mr. Winningham will remain Chairman of the Board of Directors of Theravance, Inc. and will transition to full time Chief Executive Officer of Theravance Biopharma, Inc. ("Theravance Biopharma" as of August 15, 2014. THRXV: 28.00 (+7.07), THRX: 14.27 (-0.13), TBPH: 17.07 (-0.37)
DNAnexus Appoints David Shaywitz as Chief Medical Officer
Business Wire - Tue Aug 05, 6:30AM CDT
DNAnexus, a leader in enterprise solutions for networked genome informatics and data management, today announced the expansion of its senior leadership team with the appointment of David Shaywitz, M.D., Ph.D. as the company's first Chief Medical Officer. Shaywitz joins DNAnexus from Theravance Biopharma and will focus on leveraging the company's pioneering cloud-based genomics platform to drive clinical impact, working closely with management and engineering teams, and with external partners and collaborators.
TBPH: 17.07 (-0.37)
Theravance/Glaxo Commence Global Late stage Study on COPD - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 5:42PM CDT
Glaxo (GSK) and Theravance (THRX) initiated a phase III study in COPD.
TBPH: 17.07 (-0.37), GSK: 44.91 (+0.16), THRX: 14.27 (-0.13)
1 Special Situation Dividend Stock: Snatch Up of Stay Away?
David Williamson, The Motley Fool - Motley Fool - Sun Jul 13, 11:52AM CDT
Biotech Theravance (NASDAQ: THRX) is undergoing a radical transformation. Is this special situation a unique opportunity for dividend investors, or arre problems lurking beneath the surface. Theravance recently split in two, with the money it...
THRX: 14.27 (-0.13), TBPH: 17.07 (-0.37), GSK: 44.91 (+0.16)
Glaxo/Theravance Drug Gets Japanese Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 11:00AM CDT
Glaxo (GSK) and Theravance's (THRX) Anoro Ellipta has been approved in Japan.
TBPH: 17.07 (-0.37), GSK: 44.91 (+0.16), THRX: 14.27 (-0.13), REGN: 377.84 (+0.90)
Board Changes, Patents, Recognitions, and Technical Updates - Analyst Notes on Actavis, Celldex Therapeutics, Galena Biopharma, PTC Therapeutics and Theravance Biopharma
PR Newswire - Fri Jul 04, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Galena Biopharma, Inc. (NASDAQ: GALE), PTC Therapeutics, Inc. (NASDAQ: PTCT) and Theravance Biopharma, Inc. (NASDAQ: TBPH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4461-100free.
ACT: 245.91 (-4.47), CLDX: 13.42 (-0.06), PTCT: 40.24 (-1.93), GALE: 1.95 (-0.09), TBPH: 17.07 (-0.37), FRX: 99.00 (-0.77)
Glaxo/Theravance Seek to Expand Breo Ellipta's Label - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 10:50AM CDT
Glaxo (GSK) and Theravance (THRX) are looking to get Breo Ellipta approved for asthma in the U.S.
TBPH: 17.07 (-0.37), GSK: 44.91 (+0.16), THRX: 14.27 (-0.13), REGN: 377.84 (+0.90)
